

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



B2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 37/02, C07K 7/00, 13/00 C07K 15/00	A1	(11) International Publication Number: WO 92/07579 (43) International Publication Date: 14 May 1992 (14.05.92)
(21) International Application Number: PCT/US91/08320 (22) International Filing Date: 6 November 1991 (06.11.91) (30) Priority data: 609,915 6 November 1990 (06.11.90) US (71) Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION [US/US]; 55 Shattuck Street, Boston, MA 02115 (US). (72) Inventor: EZEKOWITZ, Raymond, Alan, Brian ; 180 Beacon Street, Boston, MA 02116 (US). (74) Agent: FREEMAN, John, W.; Fish & Richardson, 225 Franklin Street, 32nd Floor, Boston, MA 02110-2804 (US).		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>
(54) Title: SOLUBLE MANNOSE RECEPTOR PEPTIDES (57) Abstract Purified soluble recombinant peptides derived from an extracellular portion of the mannose receptor protein and fragments thereof, containing one or more carbohydrate recognition domains; nucleic acid producing these fragments, and vectors and cells including such nucleic acid are disclosed. The peptides are useful for treatment of disease.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

- 1 -

SOLUBLE
MANNOSE RECEPTOR PEPTIDES

Background of the Invention

This invention relates to the general field of
5 anti-microbial and anti-viral compounds, including
diagnostic compounds, as well as to methods and reagents
for making and using the compounds.

It is known to use as anti-microbial agents
compounds that interfere with the metabolic processes of
10 the infective cell. For example, antibacterial agents of
the sulfonamide class, as structural analogs of
p-aminobenzoic acid, block purine nucleotide synthesis in
susceptible microorganisms, while penicillin prevents the
completion of the final stages of cell wall biosynthesis.

15 A number of antiviral agents such as AZT and
suramin achieve their effect by targeting the uniquely
retroviral enzyme reverse transcriptase. AZT has been
approved for treatment of patients with the Acquired
Immune Deficiency Syndrome (AIDS), caused by the Human
20 Immunodeficiency Virus Type 1 (HIV-1). Another anti-
viral agent, the polyanionic compound dextran sulfate,
blocks binding of virions to target cells. The soluble
mannose-binding protein prevents infection of H9
lymphoblasts by HIV-1 by binding to the high mannose
25 glycans expressed on the envelope glycoprotein of the
retrovirus (Ezekowitz et al., J. Exp. Med. 169:185-196,
1989).

Summary

In one aspect, the invention features a soluble
30 recombinant peptide comprising at least one (and
preferably two, three or more) carbohydrate recognition
domains derived from an extracellular portion of mannose
receptor protein (MRP). The peptide is capable of
specifically targeting cells expressing mannose, N-

- 2 -

acetylglucosamine, or fucose, by virtue of those carbohydrate recognition domain(s) (CRD). For example, the MRP-derived carbohydrate recognition domain can specifically bind eucaryotic or procaryotic pathogenic cells (e.g., bacteria, fungi, or viruses) having exposed configurations of the specified sugar moieties on their cell wall or on the envelope glycoprotein. In addition, a peptide containing the MRP-derived CRD can specifically target cancer cells which have any exposed mannose residues as a result of abberant glycosylation. Peptides according to the invention offer a probe for such cells, or a tool for delivery of specific molecules (e.g., toxins or cell specific molecules such as the T-cell antigen, CD4) to those cells, or an in vivo marker for those cells to the immune system. The domain(s) are said to be MRP-derived in that they generally contain at least 150, or preferably 300 contiguous amino acids homologous to a sequence of one or more carbohydrate recognition domains of the mannose receptor protein, shown in Fig. 3.

The soluble peptide lacks the transmembrane and cytoplasmic regions of MRP. By peptide is meant a chain of about ten or more amino acids, including larger polypeptides and proteins, that are useful in this invention. The peptide may be glycosylated via O- or N-linkages. By recombinant peptide is meant a peptide that is expressed from engineered nucleic acid, defined below.

In another aspect, the invention features engineered nucleic acid (preferably cDNA) encoding such a soluble peptide. By engineered nucleic acid is meant nucleic acid removed from its natural environment (i.e., from naturally adjacent nucleic acid) by purification or recombinant DNA methodology; the term also includes synthetic nucleic acid or cDNA. This nucleic acid may be a fragment of DNA or RNA, it may be present in a vector system (e.g., a plasmid, cosmid or phage), or it may be

- 3 -

within the genome of an organism. In some cases, such nucleic acid is purified and includes a homogeneous preparation of desired nucleic acid.

In preferred embodiments, the peptide and nucleic acid encoding it are further characterized by at least 75% identity at the amino acid level to a sequence of at least 150, and preferably 300, contiguous amino acids of one or more carbohydrate recognition domains of mannose receptor protein most preferably the peptide includes the entire extracellular region of mannose receptor protein. In other preferred embodiments, the nucleic acid substantially corresponds to at least 450 contiguous bases of the nucleic acid encoding the soluble extracellular fragment of mannose receptor protein, deposited in the ATCC as ATCC No. 68430 and described herein as nucleotides 1-4212 of SEQ ID NO: 1; and the nucleic acid is ligated to nucleic acid encoding the toxic part of a toxin molecule (e.g., AZT, ricin, or cholera toxin), or to nucleic acid encoding a peptide capable of fixing complement. The hybrid peptides encoded by such ligated nucleic acid are especially useful for causing an effector molecule to be targeted to an undesired cell or other organism, such as a virus.

The peptides described above, and antibodies to those peptides, may be used in therapeutic or diagnostic agents. Preferably the peptide is purified, that is, the peptide is substantially separated from contaminating peptides. Most preferably it is provided as a homogenous preparation admixed in a carrier substance suitable for therapeutic use. By therapeutic agent is meant a substance useful for the treatment of a disease or disorder; by diagnostic agent is meant a substance relating to the detection of a disease or disorder.

In yet other aspects, the invention features methods for treating an animal, e.g., a human, infected

- 4 -

with a bacterium, fungus, or virus. (By bacterium, fungus, or virus is meant to include any type of undesired cell or other organism that is capable of causing an infection.) One such method includes

5 providing and administering a therapeutically effective amount of a therapeutic agent or peptide including a soluble extracellular portion of mannose receptor protein capable of specifically targeting cells expressing mannose, N-acetylglucosamine, or fucose. The therapeutic

10 agent or peptide causes direct inhibition of growth of the infective organism, or causes host defensive cells, e.g., macrophages, to be attracted to the pathogenic organisms which are thereby inactivated. Such inactivation may be aided by the presence of complement

15 which is fixed by the peptide. A therapeutically effective amount is that quantity which produces a significant physiological effect in the patient and is recognized by those of ordinary skill in the art to depend upon the size and weight of the animal as well as

20 other well known factors.

In preferred embodiments, the peptide is a therapeutically effective fragment of the soluble extracellular portion of mannose receptor protein; the peptide is able to inhibit (e.g., reduce or prevent)

25 growth of, or infection by, the bacterium, fungus, or virus, and is a peptide as described above. Most preferably, the animal is human; the infection is one that results in a bacteremia or local bacterial infection, parasitic infection, or fungal colonization,

30 and the route of administration is either intravenous, intramuscular, oral, or local, e.g., in the form of a powder, or lotion, preferably at 5-100 $\mu\text{g/ml}$, more preferably at 25 $\mu\text{g/ml}$; or the virus is HIV or a related virus, and the peptide lowers the rate of infection of

35 eucaryotic cells by the virus; the protein or peptide is

- 5 -

provided at 1-500 $\mu\text{g/ml}$ (preferably 100-150 $\mu\text{g/ml}$) final concentration in human serum or tissue. Alternatively, lipid vesicles, or lyposomes, containing toxins or antibiotics are coated with the peptide and administered directly to the patient. Such lyposomes will be targeted to the infected area by the peptide and the content of the lyposomes released, thereby specifically retarding or preventing growth of the targeted cells or organisms in the targeted area.

10 In a related aspect, the invention features a coated catheter, useful for long-term administration of fluids to a patient. The catheter is coated with one of the above-described peptides, e.g., by impregnating the catheter material with the peptide. The peptide lowers the rate of bacterial, fungal or viral infection of the patient through the catheter.

In another aspect, the invention features a method for diagnosing infection by a bacterium, fungus or virus. The method includes detecting the serum level of a pathogen that expresses one of the target glycoproteins recognized by MRP, by measuring the amount of binding of a peptide according to the invention to a sample of the serum. The detected pathogen level reflects the infection of the patient. Preferably, the method features measuring the peptide by immunologic or fluorescent techniques.

In a related aspect, the invention features a purified antibody specifically recognizing a peptide according to the invention. The antibody is preferably provided as a homogeneous preparation of a monoclonal or polyclonal antibody. The antibody is useful for purification of the extracellular portion of mannose receptor protein or peptides thereof, according to the invention, and for diagnosis of infection as disclosed above.

- 6 -

In a final aspect, the invention features a purified soluble peptide comprising the extracellular portion of mannose receptor protein, said peptide lacking the mannose receptor protein transmembrane and cytoplasmic regions.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Brief Description of the Drawings

Fig. 1a shows the nucleotide base sequence and the corresponding amino acid sequence of the extracellular portion of the mannose receptor protein, described herein as nucleotides 1-4212 of SEQ ID NO: 1.

Fig. 1b shows the nucleotide base sequence and the corresponding amino acid sequence of the transmembrane and cytoplasmic portions of the mannose receptor protein, described herein as nucleotides 1-4212 of SEQ ID NO: 2.

Fig. 2 is a schematic diagram including the functional regions of the extracellular portion of the mannose receptor protein.

Fig. 3 shows the correspondance of the amino acid sequence of the various carbohydrate recognition domains of the mannose receptor, using the single letter amino acid code.

Description of the Preferred Embodiment

Soluble recombinant peptides derived from an extracellular portion of the mannose receptor that contains one or more carbohydrate recognition domains (CRDs) are able to recognize carbohydrates with a specificity comparable to that of the native membrane-bound mannose receptor. Such soluble mannose receptor peptides can be immobilized or attached to a portion of another molecule without losing effective carbohydrate recognition capacity.

- 7 -

Exposed sugars like mannose and N-acetylglucosamine are a feature of the cell walls of many pathogens, whereas higher organisms, including humans and animals, tend to have masked internal mannose residues that are not recognized by the mannose receptor. Therefore, soluble mannose receptor peptides according to the invention are useful in therapeutic agents in that they specifically bind mannose-rich pathogens, including bacteria, fungi, yeasts, parasites, or the envelope glycoproteins of certain viruses. Such peptides can also specifically target cancer cells having exposed mannose residues as a result of aberrant glycosylation. When such soluble peptides are attached to other entities such as macrophages or peptide portions that fix complement, or used as a tool for the delivery of specific molecules such as toxins or cell-specific agents to mannose-rich pathogens, the peptides can direct removal of such pathogens from the patient. The soluble peptides according to the invention are also useful as probes in diagnosis.

The amino acid sequence of the mannose receptor, from which peptides according to the invention are derived, is inferred from the cDNA sequence (Figs. 1a and 1b) and analyzed below:

Referring to Fig. 2, the first domain is comprised of 134 amino acids at the NH₂ terminus. Without being bound to any theory, it appears that this cysteine-rich region is not essential to mannose targeting according to the invention, and, therefore, it may be deleted without departing from the spirit of the invention. Preferred soluble peptides according to the invention, however, include this domain.

The second domain spans from residues 135-188. Without being bound to any theory, this domain appears to be related to fibronectin type II, and it may play a role

- 8 -

in interaction with the extracellular matrix and contribute to the spreading and adhesion of tissue macrophages expressing the full length receptor. As with the first domain, the second domain is not essential to the practice of the invention, but preferred peptides include it.

Carbohydrate recognition domains (CRDs) comprise the remainder of the extracellular portion of the receptor. Specifically, there are eight segments related to C-type carbohydrate recognition domains (CRDs) of animal lectins reported by Drickamer, J. Biol. Chem. 263:9557-9560 (1988). These CRDs are discussed in greater detail below, and they are central to the invention.

A transmembrane region and a COOH-terminal cytoplasmic domain are truncated from the receptor in peptides according to the invention to enhance solubility and facilitate therapeutic application of such peptides. Surprisingly, after truncation of the transmembrane and intracellular portions of the receptor, the molecule retains carbohydrate binding capacity effective for various purposes discussed elsewhere in this application.

Preferred peptides according to the invention include at least one or more, and preferably four or more, of the eight carbohydrate recognition domains (CRDs) depicted in Fig. 2. The sequences of the individual CRDs are shown in Fig. 3 with the numbering of the starting amino acid of each CRD keyed to the amino acid sequence of the entire soluble extracellular portion of the mannose receptor as shown in Fig. 1a, nucleotides 1-4212 of SEQ ID NO: 1.

Those skilled in the art will recognize that it is possible to vary the specific sequence of the soluble carbohydrate-targeting peptide being used, without deviating from the concept and spirit of the invention.

- 9 -

The entire extracellular portion of the mannose receptor, truncated to remove the transmembrane portion and the cytoplasmic tail of the full length receptor, is a preferred peptide, but CRD-containing fragments of the truncated receptor are also within the scope of the invention.

Not only does the invention cover CRD containing fragments of the truncated receptor, it also covers conservative mutations of the truncated receptor and its fragments. Preferably, a peptide according to the invention includes multiple (two or more and, preferably, four or more) CRDs of mannose receptor protein. Moreover, individual CRDs can be repeated to further increase the carbohydrate binding capacity of the peptide according to the invention. Merely by way of example, and not as a limitation, the peptide can include multiple copies of one or more of the specific CRDs of the mannose receptor, shown in Fig. 3.

Isolated nucleic acid encoding a CRD of mannose receptor protein is useful for producing recombinant peptide fragments of the protein. In addition, the nucleic acid can be modified by standard techniques in order to express the same or modified peptides; e.g., by conservative base substitution the nucleic acid can be modified and still encode the same amino acid sequence, or the nucleic acid can be modified to encode a conservative amino acid substitution, which will preserve the tertiary structure and the distribution of charged amino acids in the peptide.

We now describe a specific cDNA clone of the extracellular portion (ectodomain) of mannose receptor protein (MRP). The clone is described not only as a specific example of the invention but also as a starting material to obtain other peptides according to the invention, using methods of producing candidate peptides

- 10 -

and methods for screening such candidates for mannose affinity, as described below.

Example 1: Cloning of Full Length MRP and Processing of MRP cDNA to encode and express peptides of the invention

5 Sequences for probes were determined by obtaining sequence information from purified receptor. Receptor was purified from alveolar macrophages or human placenta as described (Lennartz et al., J. Biol. Chem. 262:9942, 1987).

10 Degenerate oligonucleotide probes were synthesized on a Dupont oligonucleotide synthesizer, purified by gel filtration, and labeled with ³²p-ATP and polynucleotide kinase. Radiolabeled probe was used to screen a pCDM8 placental cDNA library (gift of Dr. B. Seed, Harvard
15 Medical School) by colony hybridization. Twenty-five positive clones were isolated by two rounds of amplification and analyzed. The longest clone (3.3kb) was found upon analysis to contain sequences encoding a number of peptides that had been derived from the
20 placental mannose receptor (Taylor et al., J. Biol. Chem. 265:12156, 1990). This 3.3kb placental derived clone was radiolabeled and used as a probe to isolate the macrophage mannose receptor cDNAs from a 7 day macrophage cDNA library (Ezekowitz et al., J. Exp. Med., in press,
25 December, 1990). A 750bp cDNA derived from the 5' extent of the placental mannose receptor cDNA was utilized to isolate 5' clones from the macrophage library. A full-length cDNA was then assembled in a CDM8 expression vector.

30 The sequence of macrophage mannose receptor is identical to the placental form except for a C to T polymorphism at nucleotide 2284. The initial placental clone was sequenced by double stranded sequencing using a modified T7 polymerase, Sequenase® (U.S. Biochemical,
35 Cleveland, Ohio) based on the Sanger chain termination

- 11 -

method (Sanger et al., Proc. Natl. Acad. Sci., USA 74:5463, 1977). Specific oligonucleotides were synthesized and used as sequencing primers. For phage clones, 2 μ l of purified stock was annealed to λ GT11 primers from each of the arms and the taq polymerase amplified product obtained after 25 cycles (94°C, 30s denaturation, 55°C 30s annealing, and 72°C 3 minute extension) on a thermal cycler (Dorfman et al., Bio. Techniques, 7:568, 1989), and the products were gel purified by agarose gel electrophoresis. The purified products were digested with EcoRI, subcloned into a pUC-19 vector, and the nucleotide sequence determined as described above.

The encoded protein sequence deduced from the nucleotide sequence is shown in Figs. 1a and 1b (SEQ ID NO: 1). The open reading frame predicts a protein of 1438 amino acids which is consistent with the estimated molecular weight of the receptor polypeptide (150kD) after the N-linked sugars have been removed. (Lennartz et al., J. Biol. Chem. 264:2385, 1989; Taylor et al., J. Biol. Chem. 265:12156, 1990; Ezekowitz et al., J. Exp. Med., in press, December, 1990).

The features of the membrane bound mannose receptor protein are depicted in a schematic diagram (Fig. 2) and include (i) a typical hydrophobic signal peptide; (ii) a cysteine rich NH₂ terminal region; (iii) a fibronectin type II domain; (iv) eight carbohydrate recognition domains; (v) a hydrophobic transmembrane region; and (vi) a cytoplasmic tail. The NH₂ terminal amino acid is defined by an N-terminus peptide as Leu, which is preceded by Ala-Val-Leu, a typical recognition sequence for a signal peptidase (Von Heijne, Eur. J. Biochem. 133:17, 1983).

For encoding and expressing peptides of the invention, cDNA encoding the full length mannose receptor

- 12 -

protein (MRP) was first derived in a CDM8 plasmid expression vector as described above. A construct of the cDNA encoding soluble mannose receptor peptide was then prepared in a CDM8 plasmid by a multiple step procedure, as follows.

Referring to Figs. 1a and 1b, in the first step: an antisense primer was designed from a 3' end, at base pair 4169, to a 5' end, at base pair 4201, to contain a HpaI site. The sense primer was prepared from a 5' end at base pair 3475 and encompassed the NsiI site base pair 3510. The primers were annealed to full length mannose receptor cDNA, and a 726 base pair fragment was amplified using the polymerase chain reaction technique (PCR). The full length cDNA mannose receptor in CDM8 was then digested with NsiI and HpaI which released a fragment from the unique NsiI site in the cDNA to the HpaI site in the vector, thereby removing (see Figs. 1a and 2) the last three amino acids of the ectodomain, the entire transmembrane region, the entire cytoplasmic domain, and some vector sequence. This fragment was replaced with the 726 bp PCR fragment, thereby creating a clone (SMR), confirmed by sequence analysis, which contained cDNA encoding the signal peptide and the entire ectodomain of the mannose receptor (except for the last three amino acids). This clone is capable of generating a soluble mannose receptor peptide. This construct can be transfected stably or transiently into a mammalian expression system, and the soluble receptor peptide expressed is secreted into the medium.

From this plasmid, which has been deposited in the ATCC as ATCC No. 68430, a series of truncated forms of soluble mannose receptor peptide containing various numbers of carbohydrate recognition domains can be constructed by standard molecular biological techniques, either by using the polymerase chain reaction or

- 13 -

convenient restriction enzyme sites to create molecules that can be secreted. Alternatively, standard molecular biological techniques may be used to isolate other nucleic acid (especially cDNA) clones encoding the
5 extracellular portion of the mannose receptor protein by procedures analogous to those described above.

Expression vectors suitable for peptide expression also include standard bacterial, yeast, and viral expression vectors, as well as eucaryotic vectors. Those
10 skilled in the art will realize that such vectors generally are suitable for expressing peptides of the invention.

Expression of soluble human mannose receptor peptides by these vectors and organisms can be followed
15 using a mannan affinity column such as sepharose-mannose. The column is first contacted with the expressed material. Peptides able to recognize and bind mannose are bound to the mannose-sepharose matrix, eluted with 50mM Tris/10M EDTA, and identified using 8%
20 polyacrylamide gels (with Laemmli buffers, Nature 227:600, 1970). Those clones which produce peptides able to bind to such a column are among those useful in this invention.

USE OF THE PEPTIDES

25 Soluble mannose receptor peptides expressed as described above are useful for specifically targeting (or specifically recognizing) cells expressing carbohydrates such as mannose, N-acetylglucosamine, or fucose on their surface. Thus these peptides are useful in agents for
30 diagnosing or treating infection by a wide variety of pathogenic organisms, e.g., Leishmania proamastigotes, Pneumocystis carinii, Candida albicans, Microbacteria tuberculosis (and other atypical mycobacteria), Human Immunodeficiency Virus Type 1 (HIV-1) or influenza virus.
35 Such agents are also useful for treating opportunistic

- 14 -

infections such as those that arise in patients with cancer, patients undergoing chemotherapy or bone marrow transplants, or patients suffering from congenital or acquired immune deficiency diseases, such as AIDS. In addition, such agents can specifically target cancer cells having exposed mannose residues as a result of aberrant glycosylation.

For non-viral pathogens, removal by host defense mechanisms is achieved by directing attachment of a soluble mannose receptor peptide, in conjunction with the cell attachment site of a receptor such as the mannose-binding protein, to the surface of phagocytic cells, thereby enhancing the clearance of the pathogens from the circulation by causing the phagocytes to recognize the pathogens. For viruses which express mannose-rich glycoproteins, direct inactivation of the virus and viral infected cells is accomplished by attaching toxins, such as ricin, cholera, diphtheria, or pertussis, or antimetabolic drugs, such as AZT, to a therapeutic soluble mannose receptor peptide. The hybrid peptide thus formed can serve to kill or inhibit growth of the target cell, such as HIV.

To form such hybrid peptides, nucleic acid encoding such toxins can be ligated by well known techniques to nucleic acid encoding a soluble mannose receptor peptide according to the invention, and the fused nucleic acid can be expressed as a single entity to form a hybrid peptide (for example, as described by Murphy, U.S. Patent No. 4,675,383, hereby incorporated by reference). (By ligated is meant linked enzymatically or chemically to form a single nucleic acid entity.) Alternatively, the two peptides can be synthesized separately and linked chemically (for example, as described by Ross, U.S. Patent No. 4,275,000, hereby incorporated by reference).

- 15 -

Alternatively, nucleic acid encoding a complement-fixing region, e.g., the complement-fixing region of the immunoglobulin heavy chain or of the mannose-binding protein, can be engineered by standard techniques to form a hybrid molecule with nucleic acid encoding a soluble mannose receptor protein. The expression product of such nucleic acid can be used to target cells with exposed surface carbohydrate moieties and then to interact with complement components and activate complement. Activated complement will then stimulate binding of macrophages to the targeted pathogenic cells and their subsequent ingestion by the macrophages.

Example 2: Preparation
of a fusion protein

A soluble mannose receptor peptide-immunoglobulin fusion protein can be prepared by digesting cDNA encoding soluble mannose receptor peptide and inserting an oligonucleotide linker (e.g., a BamH1 linker). The resulting plasmid can be digested with BamH1, and the portion encoding the entire extracellular domain can be ligated to the synthetic splice donor sequence of an immunoglobulin (e.g., human IgG1) expression plasmid (Aruffo et al., Cell 61:1303-1313, 1990). Such expression vectors contain in their 3' region the immunoglobulin heavy chain constant regions two and three, which have the capacity to fix complement. A fusion protein expressed from such a fused cDNA sequence would contain a complement-fixing region at the 3' end of a soluble mannose receptor peptide.

In another construct, cDNA encoding an immunoglobulin signal peptide fused to the NH₂ terminal region, cell-attachment domain, and complement-fixing region of the mannose-binding protein (Ezekowitz, International Patent Application No. WO 89/01519, February 23, 1989) can be engineered to replace the

- 16 -

cysteine-rich and fibronectin binding domains of a soluble mannose receptor peptide. The fusion protein expressed from such a cDNA sequence would contain a complement-fixing region in the amino terminal portion of the molecule, preceding the carbohydrate recognition domains.

Soluble mannose receptor peptides according to the invention may be administered by routine methods in pharmaceutically acceptable carrier substances, i.e., inert substances suitable for pharmaceutical use such as the dispensing of drugs or medicine. For example, they can be administered in an aerosol form to treat, e.g., *Pneumocystis carinii*. Alternatively, they may be administered orally or parenterally, e.g., they can be injected directly into the blood stream of an animal, especially humans, to a level of between 1-500 $\mu\text{g/ml}$ serum (most preferably, 100-150 $\mu\text{g/ml}$) final concentration, and this dose repeated to maintain this level. The peptides can be administered prophylactically or after infection.

In a specific prophylactic use, soluble mannose receptor peptides may be used to coat intravenous or urethral catheters (e.g., by chemical impregnation of the catheter material with the peptide) to prevent infection in immunocompromised patients (e.g., cancer patients subjected to long term intravenous chemotherapy). Such catheters will bind infective organisms and prevent their entry into the patient.

In a specific therapeutic use, the soluble mannose receptor peptide may be applied topically in powder or lotion form (at a concentration of between 56-100 $\mu\text{g/ml}$), for example, to treat local infections, such as bacterial infection, yeast infection, or infection with Trichophyton, which causes athlete's foot.

- 17 -

Soluble mannose receptor peptides can also be used as a diagnostic tool, e.g., for the diagnosis of fungal diseases. Fungi infecting an animal will shed a mannose-rich polysaccharide into the serum. A sample of serum from a patient (e.g., 100 μ l) can be analyzed with fluorescently-labelled soluble mannose receptor peptide to observe binding to the fungal polysaccharide coat, and the degree of binding can be related to the degree of fungal infection remaining following a course of treatment. In an alternative diagnostic method, the degree of binding of the soluble mannose receptor peptide can be detected by using a labelled antibody that specifically recognizes the peptide. Appropriate subsequent treatment can be planned accordingly.

15 Other Embodiments

As described above, the invention generally features peptides that include a MRP-derived carbohydrate recognition domain. The genetic material encoding soluble mannose receptor peptide (deposited as described above as ATCC No. 68430) can be used to generate a large number of recombinant peptides by fragmenting the full-length nucleic acid and expressing candidate fragments. Alternatively, as described above, standard molecular biological techniques may be used to isolate other nucleic acid (especially cDNA) clones encoding soluble mannose receptor peptides. These clones can also be used to express candidate fragment peptides. As described, preferred fragments are those containing multiple CRDs. Various assays may be used to determine whether a particular candidate peptide has carbohydrate recognition ability.

In addition to the affinity column chromatographic assay described above, another assay invokes binding and uptake of I¹²⁵-labeled mannose-BSA. Specifically, mannose-BSA (EY Labs, CA) is radiolabeled as described

- 18 -

(Ezekowitz et al., J. Exp. Med. 154:60, 1981), and binding and uptake of radiolabeled ligand is performed on COS-I cells transfected with cloned cDNA encoding the candidate peptide. COS-I cells transfected with CD64
5 serve as controls, and thioglycollate elicited mouse peritoneal macrophages serve as a positive control.

Another assay utilizes antibody that specifically recognizes a soluble mannose receptor peptide. The antibody may be linked with a fluorescent tag and
10 antibody-peptide binding identified flow cytometrically. Alternatively, the antibody may be immobilized for assay use or employed in an enzyme linked immunosorbent assay or ELISA test.

Deposits

15 Plasmid SMR, in CDM8 in E-coli strain MC1061/P3, was deposited on Oct. 2, 1990, with the American Type Culture Collection (ATCC) as ATCC No. 68430.

Applicant's assignee, Children's Medical Center Corporation, represents that the ATCC is a depository
20 affording permanence of the deposit and ready accessibility thereto by the public if a patent is granted. All restrictions on the availability to the public of the material so deposited will be irrevocably removed upon the granting of a patent. The material will
25 be available during the pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 CFR 1.14 and 35 USC 122. The deposited material will be maintained with all the care necessary to keep it viable and uncontaminated for a
30 period of at least five years after the most recent request for the furnishing of a sample of the deposited microorganism, and in any case, for a period of at least thirty (30) years after the date of deposit or for the enforceable life of the patent, whichever period is
35 longer. Applicant's assignee acknowledges its duty to

- 19 -

replace the deposit should the depository be unable to furnish a sample when requested due to the condition of the deposit.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Ezekowitz, Raymond Alan Brian

(ii) TITLE OF INVENTION: SOLUBLE MANNOSE RECEPTOR PEPTIDES

5 (iii) NUMBER OF SEQUENCES: 1

(iv) CORRESPONDENCE ADDRESS:

10 (A) ADDRESSEE: Fish & Richardson
(B) STREET: One Financial Center
(C) CITY: Boston
(D) STATE: Massachusetts
(E) COUNTRY: U.S.A.
(F) ZIP CODE: 02111-2658

(v) COMPUTER READABLE FORM:

15 (A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
(B) COMPUTER: IBM PS/2 Model 50Z or 55SX
(C) OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
(D) SOFTWARE: WordPerfect (Version 5.0)

(vi) CURRENT APPLICATION DATA:

20 (A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

25 Prior applications total,
including application
described below: 0

(A) APPLICATION NUMBER: 0
(B) FILING DATE: 0

(viii) ATTORNEY/AGENT INFORMATION:

30 (A) NAME: Freeman, John W.
(B) REGISTRATION NUMBER: 29,066
(C) REFERENCE/DOCKET NUMBER: 00108-032001

(ix) TELECOMMUNICATION INFORMATION:

35 (A) TELEPHONE: (617) 542-5070
(B) TELEFAX: (617) 542-8906
(C) TELEX: 200154

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 1

(i) SEQUENCE CHARACTERISTICS:

40 (A) LENGTH: 5145 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO. 1:

- 21 -

	TTGCGTCTTA GTTCCGCCCT CCTGTCCATC AGGAGAAGGA AAGGATAAAC CCTGGGCC	63
	ATG AGG CTA CCC CTG CTC CTG GTT TTT GCC TCT GTC ATT CCG GGT GCT Met Arg Leu Pro Leu Leu Leu Val Phe Ala Ser Val Ile Pro Gly Ala -15 -10 -5	111
5	GTT CTC CTA CTG GAC ACC AGG CAA TTT TTA ATC TAT AAT GAA GAT CAC Val Leu Leu Leu Asp Thr Arg Gln Phe Leu Ile Tyr Asn Glu Asp His 1 5 10	159
10	AAG CGC TGC GTG GAT GCA GTG AGT CCC AGT GCC GTC CAA ACC GCA GCT Lys Arg Cys Val Asp Ala Val Ser Pro Ser Ala Val Gln Thr Ala Ala 15 20 25 30	207
	TGC AAC CAG GAT GCC GAA TCA CAG AAA TTC CGA TGG GTG TCC GAA TCT Cys Asn Gln Asp Ala Glu Ser Gln Lys Phe Arg Trp Val Ser Glu Ser 35 40 45	255
15	CAG ATT ATG AGT GTT GCA TTT AAA TTA TGC CTG GGA GTG CCA TCA AAA Gln Ile Met Ser Val Ala Phe Lys Leu Cys Leu Gly Val Pro Ser Lys 50 55 60	303
	ACA GAC TGG GTT GCT ATC ACT CTC TAT GCC TGT GAC TCA AAA AGT GAA Thr Asp Trp Val Ala Ile Thr Leu Tyr Ala Cys Asp Ser Lys Ser Glu 65 70 75	351
20	TTT CAG AAA TGG GAG TGC AAA AAT GAC ACA CTT TTG GGG ATC AAA GGA Phe Gln Lys Trp Glu Cys Lys Asn Asp Thr Leu Leu Gly Ile Lys Gly 80 85 90	399
25	GAA GAT TTA TTT TTT AAC TAC GGC AAC AGA CAA GAA AAG AAT ATT ATG Glu Asp Leu Phe Phe Asn Tyr Gly Asn Arg Gln Glu Lys Asn Ile Met 95 100 105 110	447
	CTC TAC AAG GGA TCG GGT TTA TGG AGC AGG TGG AAG ATC TAT GGA ACC Leu Tyr Lys Gly Ser Gly Leu Trp Ser Arg Trp Lys Ile Tyr Gly Thr 115 120 125	495
30	ACA GAC AAT CTG TGC TCC AGA GGT TAT GAA GCC ATG TAT ACG CTA CTA Thr Asp Asn Leu Cys Ser Arg Gly Tyr Glu Ala Met Tyr Thr Leu Leu 130 135 140	543
	GGC AAT GCC AAT GGA GCA ACC TGT GCA TTC CCG TTC AAG TTT GAA AAC Gly Asn Ala Asn Gly Ala Thr Cys Ala Phe Pro Phe Lys Phe Glu Asn 145 150 155	591
35	AAG TGG TAC GCA GAT TGC ACG AGT GCT GGG CGG TCG GAT GGA TGG CTC Lys Trp Tyr Ala Asp Cys Thr Ser Ala Gly Arg Ser Asp Gly Trp Leu 160 165 170	639
40	TGG TGC GGA ACC ACT ACT GAC TAT GAC ACA GAC AAG CTA TTT GGA TAT Trp Cys Gly Thr Thr Thr Asp Tyr Asp Thr Asp Lys Leu Phe Gly Tyr 175 180 185 190	687
	TGT CCA TTG AAA TTT GAG GGC AGT GAA AGC TTA TGG AAT AAA GAC CCG Cys Pro Leu Lys Phe Glu Gly Ser Glu Ser Leu Trp Asn Lys Asp Pro 195 200 205	735
45	CTG ACC AGC GTT TCC TAC CAG ATA AAC TCC AAA TCC GCT TTA ACG TGG Leu Thr Ser Val Ser Tyr Gln Ile Asn Ser Lys Ser Ala Leu Thr Trp 210 215 220	783
	CAC CAA GCG AGG AAA AGC TGC CAA CAA CAG AAC GCT GAG CTC CTG AGC	831

- 22 -

	His Gln Ala Arg Lys Ser Cys Gln Gln Gln Asn Ala Glu Leu Leu Ser	
	225 230 235	
5	ATC ACA GAG ATA CAT GAG CAA ACA TAC CTG ACA GGA TTA ACC AGT TCC Ile Thr Glu Ile His Glu Gln Thr Tyr Leu Thr Gly Leu Thr Ser Ser	879
	240 245 250	
	TTG ACC TCA GGA CTC TGG ATT GGA CTT AAC AGT CTG AGC TTC AAC AGC Leu Thr Ser Gly Leu Trp Ile Gly Leu Asn Ser Leu Ser Phe Asn Ser	927
	255 260 265 270	
10	GGT TGG CAG TGG AGT GAC CGC AGT CCT TTC CGA TAT TTG AAC TGG TTA Gly Trp Gln Trp Ser Asp Arg Ser Pro Phe Arg Tyr Leu Asn Trp Leu	975
	275 280 285	
	CCA GGA AGT CCA TCA GCT GAA CCT GGA AAA AGC TGT GTG TCA CTA AAT Pro Gly Ser Pro Ser Ala Glu Pro Gly Lys Ser Cys Val Ser Leu Asn	1023
	290 295 300	
15	CCT GGA AAA AAT GCT AAA TGG GAA AAT CTG GAA TGT GTT CAG AAA CTG Pro Gly Lys Asn Ala Lys Trp Glu Asn Leu Glu Cys Val Gln Lys Leu	1071
	305 310 315	
20	GGC TAT ATT TGC AAA AAG GGC AAC ACC ACT TTA AAT TCT TTT GTT ATT Gly Tyr Ile Cys Lys Lys Gly Asn Thr Thr Leu Asn Ser Phe Val Ile	1119
	320 325 330	
	CCC TCA GAA AGT GAT GTG CCT ACT CAC TGT CCT AGT CAG TGG TGG CCG Pro Ser Glu Ser Asp Val Pro Thr His Cys Pro Ser Gln Trp Trp Pro	1167
	335 340 345 350	
25	TAT GCC GGT CAC TGT TAC AAG ATT CAC AGA GAT GAG AAA AAA ATC CAG Tyr Ala Gly His Cys Tyr Lys Ile His Arg Asp Glu Lys Lys Ile Gln	1215
	355 360 365	
	AGG GAT GCT CTG ACC ACC TGC AGG AAG GAA GGC GGT GAC CTC ACA AGT Arg Asp Ala Leu Thr Thr Cys Arg Lys Glu Gly Gly Asp Leu Thr Ser	1263
	370 375 380	
30	ATC CAC ACC ATC GAG GAA TTG GAC TTT ATT ATC TCC CAG CTA GGA TAT Ile His Thr Ile Glu Glu Leu Asp Phe Ile Ile Ser Gln Leu Gly Tyr	1311
	385 390 395	
35	GAG CCA AAT GAC GAA TTG TGG ATC GGC TTA AAT GAC ATT AAG ATT CAA Glu Pro Asn Asp Glu Leu Trp Ile Gly Leu Asn Asp Ile Lys Ile Gln	1359
	400 405 410	
	ATG TAC TTT GAG TGG AGT GAT GGG ACC CCT GTA ACG TTT ACC AAA TGG Met Tyr Phe Glu Trp Ser Asp Gly Thr Pro Val Thr Phe Thr Lys Trp	1407
	415 420 425 430	
40	CTT CGT GGA GAA CCA AGC CAT GAA AAC AAC AGA CAG GAG GAT TGT GTG Leu Arg Gly Glu Pro Ser His Glu Asn Asn Arg Gln Glu Asp Cys Val	1455
	435 440 445	
	GTG ATG AAA GGC AAG GAT GGG TAC TGG GCA GAT CGG GGC TGT GAG TGG Val Met Lys Gly Lys Asp Gly Tyr Trp Ala Asp Arg Gly Cys Glu Trp	1503
	450 455 460	
45	CCT CTT GGC TAC ATC TGC AAG ATG AAA TCA CGA AGC CAA GGT CCA GAA Pro Leu Gly Tyr Ile Cys Lys Met Lys Ser Arg Ser Gln Gly Pro Glu	1551
	465 470 475	

- 23 -

	ATA GTG GAA GTC GAA AAA GGC TGC AGG AAA GGC TGG AAA AAA CAT CAC Ile Val Glu Val Glu Lys Gly Cys Arg Lys Gly Trp Lys Lys His His 480 485 490	1599
5	TTT TAC TGC TAT ATG ATT GGA CAT ACG CTT TCA ACA TTT GCA GAA GCA Phe Tyr Cys Tyr Met Ile Gly His Thr Leu Ser Thr Phe Ala Glu Ala 495 500 505	1647
	AAC CAA ACC TGT AAT AAT GAG AAT GCT TAT TTA ACA ACT ATT GAA GAC Asn Gln Thr Cys Asn Asn Glu Asn Ala Tyr Leu Thr Thr Ile Glu Asp 510 515 520 525	1695
10	AGA TAT GAA CAA GCC TTC CTG ACT AGT TTC GTT GGC TTA AGG CCT GAA Arg Tyr Glu Gln Ala Phe Leu Thr Ser Phe Val Gly Leu Arg Pro Glu 530 535 540	1743
15	AAA TAT TTC TGG ACA GGA CTT TCA GAT ATA CAA ACC AAA GGG ACT TTT Lys Tyr Phe Trp Thr Gly Leu Ser Asp Ile Gln Thr Lys Gly Thr Phe 545 550 555	1791
	CAG TGG ACC ATC GAG GAA GAG GTT CGG TTC ACC CAC TGG AAT TCA GAT Gln Trp Thr Ile Glu Glu Glu Val Arg Phe Thr His Trp Asn Ser Asp 560 565 570	1839
20	ATG CCA GGG CGA AAG CCA GGG TGT GTT GCC ATG AGA ACC GGG ATT GCA Met Pro Gly Arg Lys Pro Gly Cys Val Ala Met Arg Thr Gly Ile Ala 575 580 585	1887
	GGG GGC TTA TGG GAT GTT TTG AAA TGT GAT GAA AAG GCA AAA TTT GTG Gly Gly Leu Trp Asp Val Leu Lys Cys Asp Glu Lys Ala Lys Phe Val 590 595 600 605	1935
25	TGC AAG CAC TGG GCA GAA GGA GTA ACC CAC CCA CCG AAG CCC ACG ACG Cys Lys His Trp Ala Glu Gly Val Thr His Pro Pro Lys Pro Thr Thr 610 615 620	1983
30	ACT CCC GAA CCC AAA TGT CCG GAG GAT TGG GGC GCC AGC AGT AGA ACA Thr Pro Glu Pro Lys Cys Pro Glu Asp Trp Gly Ala Ser Ser Arg Thr 625 630 635	2031
	AGC TTG TGT TTC AAG CTG TAT GCA AAA GGA AAA CAT GAG AAG AAA ACG Ser Leu Cys Phe Lys Leu Tyr Ala Lys Gly Lys His Glu Lys Lys Thr 640 645 650	2079
35	TGG TTT GAA TCT CGA GAT TTT TGT CGA GCT CTG GGT GGA GAC TTA GCT Trp Phe Glu Ser Arg Asp Phe Cys Arg Ala Leu Gly Gly Asp Leu Ala 655 660 665	2127
	AGC ATC AAT AAC AAA GAG GAA CAG CAA ACA ATA TGG CGA TTA ATA ACA Ser Ile Asn Asn Lys Glu Glu Gln Gln Thr Ile Trp Arg Leu Ile Thr 670 675 680 685	2175
40	GCT AGT GGA AGC TAC CAC AAA CTG TTT TGG TTG GGA TTG ACA TAT GGA Ala Ser Gly Ser Tyr His Lys Leu Phe Trp Leu Gly Leu Thr Tyr Gly 690 695 700	2223
45	AGC CCT TCA GAA GGT TTT ACT TGG AGT GAT GGT TCT CCT GTT TCA TAT Ser Pro Ser Glu Gly Phe Thr Trp Ser Asp Gly Ser Pro Val Ser Tyr 705 710 715	2271
	GAA AAC TGG GCT TAT GGA GAA CCT AAT AAT TAT CAA AAT GTT GAA TAC Glu Asn Trp Ala Tyr Gly Glu Pro Asn Asn Tyr Gln Asn Val Glu Tyr 720 725 730	2319

- 24 -

	TGT GGT GAG CTG AAA GGT GAC CCT ACT ATG TCT TGG AAT GAT ATT AAT. Cys Gly Glu Leu Lys Gly Asp Pro Thr Met Ser Trp Asn Asp Ile Asn 735 740 745	2367
5	TGT GAA CAC CTT AAC AAC TGG ATT TGC CAG ATA CAA AAA GGA CAA ACA Cys Glu His Leu Asn Asn Trp Ile Cys Gln Ile Gln Lys Gly Gln Thr 750 755 760 765	2415
	CCA AAA CCT GAG CCA ACA CCA GCT CCT CAA GAC AAT CCA CCA GTT ACT Pro Lys Pro Glu Pro Thr Pro Ala Pro Gln Asp Asn Pro Pro Val Thr 770 775 780	2463
10	GAA GAT GGG TGG GTT ATT TAC AAA GAC TAC CAG TAT TAT TTC AGC AAA Glu Asp Gly Trp Val Ile Tyr Lys Asp Tyr Gln Tyr Tyr Phe Ser Lys 785 790 795	2511
15	GAG AAG GAA ACC ATG GAC AAT GCG CGA GCG TTT TGC AAG AGG AAT TTT Glu Lys Glu Thr Met Asp Asn Ala Arg Ala Phe Cys Lys Arg Asn Phe 800 805 870	2559
	GGT GAT CTT GTT TCT ATT CAA AGT GAA AGT GAA AAG AAG TTT CTA TGG Gly Asp Leu Val Ser Ile Gln Ser Glu Ser Glu Lys Lys Phe Leu Trp 815 820 825	2607
20	AAA TAT GTA AAC AGA AAT GAT GCA CAG TCT GCA TAT TTT ATT GGT TTA Lys Tyr Val Asn Arg Asn Asp Ala Gln Ser Ala Tyr Phe Ile Gly Leu 830 835 840 845	2655
	TTG ATC AGC TTG GAT AAA AAG TTT GCT TGG ATG GAT GGA AGC AAA GTG Leu Ile Ser Leu Asp Lys Lys Phe Ala Trp Met Asp Gly Ser Lys Val 850 855 860	2703
25	GAT TAC GTG TCT TGG GCC ACA GGT GAA CCC AAT TTT GCA AAT GAA GAT Asp Tyr Val Ser Trp Ala Thr Gly Glu Pro Asn Phe Ala Asn Glu Asp 865 870 875	2751
30	GAA AAC TGT GTG ACC ATG TAT TCA AAT TCA GGG TTT TGG AAT GAC ATT Glu Asn Cys Val Thr Met Tyr Ser Asn Ser Gly Phe Trp Asn Asp Ile 880 885 890	2799
	AAC TGT GGC TAT CCA AAC GCC TTC ATT TGC CAG CGA CAT AAC AGT AGT Asn Cys Gly Tyr Pro Asn Ala Phe Ile Cys Gln Arg His Asn Ser Ser 895 900 905	2847
35	ATC AAT GCT ACC ACA GTT ATG CCT ACC ATG CCC TCG GTC CCA TCA GGG Ile Asn Ala Thr Thr Val Met Pro Thr Met Pro Ser Val Pro Ser Gly 910 915 920 925	2895
	TGC AAG GAA GGT TGG AAT TTC TAC AGC AAC AAG TGT TTC AAA ATC TTT Cys Lys Glu Gly Trp Asn Phe Tyr Ser Asn Lys Cys Phe Lys Ile Phe 930 935 940	2943
40	GGA TTT ATG GAA GAA GAA AGA AAA AAT TGG CAA GAG GCA CGA AAA GCT Gly Phe Met Glu Glu Glu Arg Lys Asn Trp Gln Glu Ala Arg Lys Ala 945 950 955	2991
45	TGT ATA GGC TTT GGA GGG AAT CTG GTC TCC ATA CAA AAT GAA AAA GAG Cys Ile Gly Phe Gly Gly Asn Leu Val Ser Ile Gln Asn Glu Lys Glu 960 965 970	3039
	CAA GCA TTT CTT ACC TAT CAC ATG AAG GAC TCC ACT TTC AGT GCC TGG Gln Ala Phe Leu Thr Tyr His Met Lys Asp Ser Thr Phe Ser Ala Trp 975 980 985	3087

- 25 -

	ACT GGG CTG AAT GAT GTC AAT TCA GAA CAC ACG TTC CTT TGG ACG GAT Thr Gly Leu Asn Asp Val Asn Ser Glu His Thr Phe Leu Trp Thr Asp 990 995 1000 1005	3135
5	GGA CGA GGA GTC CAT TAC ACA AAC TGG GGG AAA GGT TAC CCT GGT GGA Gly Arg Gly Val His Tyr Thr Asn Trp Gly Lys Gly Tyr Pro Gly Gly 1010 1015 1020	3183
	AGA AGA AGC AGT CTT TCT TAT GAA GAT GCT GAC TGT GTT GTT ATT ATT Arg Arg Ser Ser Leu Ser Tyr Glu Asp Ala Asp Cys Val Val Ile Ile 1025 1030 1035	3231
10	GGA GGT GCA TCA AAT GAA GCA GGA AAA TGG ATG GAT GAT ACC TGC GAC Gly Gly Ala Ser Asn Glu Ala Gly Lys Trp Met Asp Asp Thr Cys Asp 1040 1045 1050	3279
15	AGT AAA CGA GGC TAC ATA TGC CAG ACA CGA TCC GAC CCT TCC TTG ACT Ser Lys Arg Gly Tyr Ile Cys Gln Thr Arg Ser Asp Pro Ser Leu Thr 1055 1060 1065	3327
	AAT CCT CCA GCA ACG ATT CAA ACA GAT GGC TTT GTT AAA TAT GGC AAA Asn Pro Pro Ala Thr Ile Gln Thr Asp Gly Phe Val Lys Tyr Gly Lys 1070 1075 1080 1090	3375
20	AGC AGC TAT TCA CTC ATG AGA CAA AAA TTT CAA TGG CAT GAA GCG GAG Ser Ser Tyr Ser Leu Met Arg Gln Lys Phe Gln Trp His Glu Ala Glu 1095 1100 1105	3423
	ACA TAC TGC AAG CTT CAC AAT TCC CTT ATA GCC AGC ATT CTG GAT CCC Thr Tyr Cys Lys Leu His Asn Ser Leu Ile Ala Ser Ile Leu Asp Pro 1110 1115 1120	3471
25	TAC AGT AAT GCA TTT GCG TGG CTG CAG ATG GAA ACA TCT AAT GAA CGT Tyr Ser Asn Ala Phe Ala Trp Leu Gln Met Glu Thr Ser Asn Glu Arg 1125 1130 1135	3519
30	GTG TGG ATC GCC CTG AAC AGT AAC TTG ACT GAT AAT CAA TAC ACT TGG Val Trp Ile Ala Leu Asn Ser Asn Leu Thr Asp Asn Gln Tyr Thr Trp 1140 1145 1150	3567
	ACT GAT AAG TGG AGG GTG AGG TAC ACT AAC TGG GCT GCT GAT GAG CCC Thr Asp Lys Trp Arg Val Arg Tyr Thr Asn Trp Ala Ala Asp Glu Pro 1155 1160 1165 1170	3615
35	AAA TTG AAA TCA GCA TGT GTT TAT CTG GAT CTT GAT GGC TAC TGG AAG Lys Leu Lys Ser Ala Cys Val Tyr Leu Asp Leu Asp Gly Tyr Trp Lys 1175 1180 1185	3663
	ACA GCA CAT TGC AAT GAA AGT TTT TAC TTT CTC TGT AAA AGA TCA GAT Thr Ala His Cys Asn Glu Ser Phe Tyr Phe Leu Cys Lys Arg Ser Asp 1190 1195 1200	3711
40	GAA ATC CCT GCT ACT GAA CCC CCA CAA CTG CCT GGC AGA TGC CCG GAG Glu Ile Pro Ala Thr Glu Pro Pro Gln Leu Pro Gly Arg Cys Pro Glu 1205 1210 1215	3759
45	TCA GAT CAC ACA GCA TGG ATT CCT TTC CAT GGT CAC TGT TAC TAT ATT Ser Asp His Thr Ala Trp Ile Pro Phe His Gly His Cys Tyr Tyr Ile 1220 1225 1230	3807
	GAG TCC TCA TAT ACA AGA AAC TGG GGC CAA GCT TCT CTG GAA TGT CTT Glu Ser Ser Tyr Thr Arg Asn Trp Gly Gln Ala Ser Leu Glu Cys Leu 1235 1240 1245 1250	3855

- 26 -

	CGA ATG GGT TCC TCT CTG GTT TCC ATT GAA AGT GCT GCA GAA TCC AGT Arg Met Gly Ser Ser Leu Val Ser Ile Glu Ser Ala Ala Glu Ser Ser 1255 1260 1265	3903
5	TTT CTG TCA TAT CGG GTT GAG CCA CTT AAA AGT AAA ACC AAT TTT TGG Phe Leu Ser Tyr Arg Val Glu Pro Leu Lys Ser Lys Thr Asn Phe Trp 1270 1275 1280	3951
	ATA GGA TTG TTC AGA AAT GTT GAA GGG ACG TGG CTG TGG ATA AAT AAC Ile Gly Leu Phe Arg Asn Val Glu Gly Thr Trp Leu Trp Ile Asn Asn 1285 1290 1295	3999
10	AGT CCG GTC TCC TTT GTC AAC TGG AAC ACA GGA GAT CCC TCT GGT GAA Ser Pro Val Ser Phe Val Asn Trp Asn Thr Gly Asp Pro Ser Gly Glu 1300 1305 1310	4047
15	CGG AAT GAT TGT GTG ACT TTA CAT GCG TCT TCT GGG TTT TGG AGT AAT Arg Asn Asp Cys Val Thr Leu His Ala Ser Ser Gly Phe Trp Ser Asn 1315 1320 1325 1330	4095
	ATT CAC TGT TCT TCC TAC AAA GGA TAT ATT TGT AAA AGA CCA AAA ATT Ile His Cys Ser Ser Tyr Lys Gly Tyr Ile Cys Lys Arg Pro Lys Ile 1335 1340 1345	4143
20	ATT GAT GCT AAA CCT ACT CAT GAA TTA CTT ACA ACA AAA GCT GAC ACA Ile Asp Ala Lys Pro Thr His Glu Leu Leu Thr Thr Lys Ala Asp Thr 1350 1355 1360	4191
	AGG AAG ATG GAC CCT TCT AAA CCG TCT TCC AAC GTG GCC GGA GTA GTC Arg Lys Met Asp Pro Ser Lys Pro Ser Ser Asn Val Ala Gly Val Val 1365 1370 1375	4239
25	ATC ATT GTG ATC CTC CTG ATT TTA ACG GGT GCT GGC CTT GCC GCC TAT Ile Ile Val Ile Leu Leu Ile Leu Thr Gly Ala Gly Leu Ala Ala Tyr 1380 1385 1390	4287
30	TTC TTT TAT AAG AAA AGA CGT GTG CAC CTA CCT CAA GAG GGC GCC TTT Phe Phe Tyr Lys Lys Arg Val His Leu Pro Gln Glu Gly Ala Phe 1395 1400 1405 1410	4335
	GAA AAC ACT CTG TAT TTT AAC AGT CAG TCA AGC CCA GGA ACT AGT GAT Glu Asn Thr Leu Tyr Phe Asn Ser Gln Ser Ser Pro Gly Thr Ser Asp 1415 1420 1425	4383
35	ATG AAA GAT CTC GTG GGC AAT ATT GAA CAG AAT GAA CAC TCG GTC ATC Met Lys Asp Leu Val Gly Asn Ile Glu Gln Asn Glu His Ser Val Ile 1430 1435 1440	4431
	TAG TACCTCAATG CGATTCTGAG ATATTGGAAT TTCATAAAAT TGTAAGTGAA End	4484
40	ATTTAAAAAT TTTAGTTCAA TGTGATTGTT TTCTTTAAAA TGAGTACTGA ATTGTACTGG TCTGTCCTTT TTTCCCTTGC CTAATTGAAG AAATAATTGC TTGTTTTCTA GCCTGGCAAG	4544 4604
	ATATTTTCAT AAAAGAGGGA TAACAATGCT GATTACTACC TTTTAAATA TTTTAGATAA	4664
	ATGCACAGCA CCACAGCAAC ACATCTAAGC ATTAGTGATG GGTAGCTGAT GTCAGCTTCA	4724
	TGTGGATTTT AAGCACTCTA GAAACAATGA AGCTTCTTGG CATATTTTAA GGAGCTCCCA	4784
45	AAATGTGTTA CCTATTAAAT TGTAAGTCAG CAAGTAGAAG ACCATTTGAA AAGTCAGGTA	4844
	CAAAATTCCT CAAGTGGCAT AAAAATGTAG TCAGTTTCT CTTTACCAG TTTTATTTC	4904

- 27 -

CACTCCAATT ATTTAGAAT TTATTTGTAC ATGTGCAGAA GAATAAGGCA GCTGAGAATC 4964
TTGTTTCCCE CAAGAGAGTT TTACAGGCTG AGTGYTGCAA ATGTGTTCTT TGTCCTGTTA 5024
TATGTATATC AGGAATACAA GGATGTGAAA TAAACTGTA AATTTGCATA ACTGGATGTA 5084
CTTAGATAAT GTGAAATAAA CATTAAAGAC AAGGTCTATT TTTAATAAAA AAAAAAAAAA 5144
A 5145

5

- 28 -

What is claimed is:

- 1 1. A soluble recombinant peptide comprising at
2 least one carbohydrate recognition domain, derived from an
3 extracellular portion of mannose receptor protein, said
4 peptide lacking the mannose receptor protein transmembrane
5 and cytoplasmic regions, said peptide being capable of
6 specifically targeting cells expressing mannose, N-
7 acetylglucosamine, or fucose.

- 1 2. The peptide of claim 1 comprising a sequence
2 with greater than 75% homology to a fragment of at least 150
3 contiguous amino acids of mannose receptor protein.

- 1 3. The peptide of claim 1 comprising at least 150
2 contiguous amino acids of mannose receptor protein.

- 1 4. The peptide of claim 1 comprising a sequence
2 with greater than 75% homology to a fragment of at least 300
3 contiguous amino acids of mannose receptor protein.

- 1 5. The peptide of claim 1 comprising at least 300
2 contiguous amino acids of mannose receptor protein.

- 1 6. The peptide of claim 1 comprising at least one
2 complete carbohydrate recognition domain from mannose
3 receptor protein, shown in Fig. 3.

- 1 7. The peptide of claim 1 comprising at least two
2 complete carbohydrate recognition domains from mannose
3 receptor protein, shown in Fig. 3.

- 29 -

1 8. The peptide of claim 1 comprising at least two
2 copies of a carbohydrate recognition domain from mannose
3 reception protein, shown in Fig. 3.

1 9. The peptide of claim 1 further comprising a
2 segment capable of fixing complement.

1 10. The peptide of claim 9 wherein said peptide
2 comprises a complement-fixing region of immunoglobulin heavy
3 chain.

1 11. The peptide of claim 1 further comprising a
2 cytotoxin.

1 12. The peptide of claim 11 wherein said cytotoxin
2 is AZT, ricin, pertussis, or cholera toxin.

1 13. Engineered nucleic acid encoding the peptide of
2 claim 1.

1 14. The engineered nucleic acid of claim 13 wherein
2 said nucleic acid is cDNA.

1 15. A nucleic acid fragment substantially
2 corresponding to at least 450 contiguous bases of the
3 nucleic acid encoding the soluble extracellular fragment of
4 mannose receptor protein (SEQ ID NO: 1), deposited in the
5 ATCC as ATCC No. 68430, said fragment encoding a soluble
6 peptide capable of specifically targeting cells expressing
7 mannose, N-acetylglucosamine, or fucose.

1 16. Engineered nucleic acid substantially
2 corresponding to the nucleic acid encoding the soluble

- 30 -

3 extracellular fragment of mannose receptor protein (SEQ ID
4 NO: 1), deposited in the ATCC as ATCC No. 68430.

1 17. An expression vector comprising the engineered
2 nucleic acid of claim 13.

1 18. A recombinant cell comprising the engineered
2 nucleic acid of claim 13.

1 19. A therapeutic agent comprising a
2 therapeutically effective amount of the peptide of claim 1
3 administered in a pharmaceutically acceptable carrier
4 substance.

1 20. The therapeutic agent of claim 19 comprising a
2 lysosome coated with the soluble peptide.

1 21. A method for treating an animal infected with a
2 bacterium, a fungus, or a virus, said method comprising the
3 steps of
4 providing the therapeutic agent of claim 19, and
5 administering to the animal a therapeutically
6 effective amount of said agent.

1 22. The method of claim 21 wherein said animal is
2 human.

1 23. The method of claim 22 wherein said peptide is
2 administered by application of a powder or a lotion
3 comprising said peptide to the foot.

- 31 -

1 24. The method of claim 21 wherein said agent
2 lowers the level of infection of eucaryotic cells by said
3 bacterium, fungus, or virus.

1 25. A purified antibody specifically recognizing
2 the peptide of claim 1.

1 26. A method for diagnosing, in an animal, an
2 infection by a bacterium, a fungus, or a virus, said method
3 comprising the steps of
4 providing a sample of serum from the animal,
5 contacting said serum with an effective amount of
6 the peptide of claim 1, and
7 measuring the amount of binding of said peptide to
8 said serum sample.

1 27. The method of claim 26 wherein said animal is
2 human and said infection is by a fungus.

1 28. The method of claim 26 wherein said measuring
2 step comprises determining the amount of binding of an
3 antibody specific for said peptide to a serum sample
4 containing said peptide.

1 29. The method of claim 26 wherein said measuring
2 step comprises fluorescence detection.

1 30. A purified soluble peptide comprising the
2 extracellular portion of mannose receptor protein, said
3 peptide lacking the mannose receptor protein transmembrane
4 and cytoplasmic regions.

1/2

[illegible][illegible]

Fig. 1b




Fig. 2

1	CRD	1	(189)	KONTUUN_SF	YQINSKAL	THQAHKSCQQQAELLSTEI	HEQDUL	TC	LT	S	SLTS	CLWICHSLSFASCH	QNSDQSPRTYLNK	PCSPSAEPG	K	SCYSLNPG	KHAKTEIN	LEVRD							
2	CRD	2	(324)	WIKSRQCP	VIPE	SOVTPH	PSQWPHAGCHTKY	MODKIN	QHD	ALTQREKQ	QTSHT	EEQFL	TSYQV	IP	MOBILWQ	QIQWY	FENDQSPVTFVTLN	RCPSHE	WARGEDQWAK	G	WQGTWADRGCEK
3	CRD	3	(470)	WIKSRQCP	CEIPEVEYER	COH	GRQKHQSPCYML	CHTSLTFAE	ANTQONEMAY	TLTDR	TEQFL	TSYQV	RP	ENYTFILQ	QIQWY	FENDQSPVTFVTLN	RCPSHE	GRQKHQWAK	G	WQGTWADRGCEK
4	CRD	4	(609)	WIKSRQCP	WHTPTTTP	K	CPED	WQSSYSLT	CFPK	YVAKNEHKT	WTFESDQ	CRAL	QAL	QSNK	SEQRQ	WTLW	TASQ	WHLQFL	Q	WQGTWADRGCEK	
5	CRD	5	(761)	WIKSRQCP	QPTAPQWPH	QV	TEQ	QWYQWYQ	QYTESCHQK	WTFESDQ	CRAL	QAL	QSNK	SEQRQ	WTLW	TASQ	WHLQFL	Q	WQGTWADRGCEK		
6	CRD	6	(906)	WIKSRQCP	WHTPTTTP	K	CPED	WQSSYSLT	CFPK	YVAKNEHKT	WTFESDQ	CRAL	QAL	QSNK	SEQRQ	WTLW	TASQ	WHLQFL	Q	WQGTWADRGCEK	
7	CRD	7	(1043)	WIKSRQCP	WHTPTTTP	K	CPED	WQSSYSLT	CFPK	YVAKNEHKT	WTFESDQ	CRAL	QAL	QSNK	SEQRQ	WTLW	TASQ	WHLQFL	Q	WQGTWADRGCEK	
8	CRD	8	(1198)	WIKSRQCP	WHTPTTTP	K	CPED	WQSSYSLT	CFPK	YVAKNEHKT	WTFESDQ	CRAL	QAL	QSNK	SEQRQ	WTLW	TASQ	WHLQFL	Q	WQGTWADRGCEK	

INTERNATIONAL SEARCH REPORT

PCT/US91/08320

International Application No.

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC(5):	A61K 37/02; C07K 7/00, 13/00, 15/00	
U.S. Cl.	530/300, 350, 395; 424/88; 514/8, 12	
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S. Cl.	530/300, 350, 395; 424/88; 514/8, 12	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸		
APS, CAS, BIOSIS, PIR, SWISS-PROT; Search terms: Mannose receptor protein; carbohydrate recognition domains (CRDs)		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	THE JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 262, No. 20, issued 15 JULY 1987, HALBERG ET AL., "Major and Minor Forms Of The Rat Liver Asialoglycoprotein Receptor Are Independent Galactose-Binding Proteins", pages 9828-9838. See the entire document.	1-12, 30
Y	JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 265, No. 21, issued 25 JULY 1990, TAYLOR ET AL. "Primary Structure Of The Mannose Receptor Contains Multiple Motifs Resembling Carbohydrate Recognition Domains", pages 12156-12162. See the entire document.	1-12, 30
Y	THE JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 262, No. 21, issued 25 JULY 1987, LENNARTZ ET AL., "Isolation And Characterization Of A Mannose-Specific Endocytosis Receptor From Human Placenta, "Pages 9942-9944, See especially the abstract, Figure 2, Table 1, page 9944, column 1.	1-12, 30
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
29 January 1992	27 FEB 1992	
International Searching Authority	Signature of Authorized Officer	
ISA/US	Lisa T. Bennett	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 261, No. 16, issued 05 JUNE 1986, HALTIWANGER ET AL., "The Isolation Of A Rat Alveolar Macrophage Lectin", Pages 7440-7444, See especially the Abstract and Table II.	1-12, 30
Y	JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 263, No. 20, issued 15 JULY 1988, DRICKAMER, Two Distinct Classes of Carbohydrate Recognition Domains In Animal Lectins", Pages 9557-9560, See especially page 9557, column 1 and 9558, column 1, paragraph 3-column 2.	1-12, 19-20 30, 25
Y	BIOCHEMICAL JOURNAL, Volume 245, Issued in 1987, LENNARTZ ET AL., "Isolation and Characterization Of A Mannose-Specific Endocytosis Receptor From Rabbit Alveolar Macrophages", Pages 705-711, See especially the Abstract, page 705, column 1, figure 2, page 708.	1-12, 30 19-20, 25
Y	BIOCHEMICAL JOURNAL, Volume 262, Issued 1989, CHILDS ET AL., "Neoglycolipids As Probes Of Oligosaccharide Recognition By Recombinant And Natural Mannose-Binding Proteins Of Rat and Man", Pages 131-138, See especially Abstract; pages 131, Column 2,-page 131, column 1 and page 136.	1-12, 30 19-20, 25
Y	JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 259, No. 3, issued 10 FEBRUARY 1984, LARGENT ET AL., "Carbohydrate-Specific Adhesion Of Alveolar Macrophages To Mannose-Derived Surfaces", Pages 1764-1769, See especially the Abstract and page 1764, column 2, figures 1-3.	1-12, 30 19-20, 25